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Background. Extensively drug-resistant (XDR) tuberculosis (TB) is a major public health threat in South
Korea.
Methods. We analyzed baseline epidemiological data for 250 patients enrolled in an ongoing prospective
observational study of TB at a large tertiary referral hospital in South Korea.
Results. Twenty-six subjects with XDR TB were identified; all were patients who had previously received TB
therapy. Cumulative previous treatment duration (range, 18–34 months; odds ratio [OR], 5.6; 95% confidence
interval [CI], 1.0–59), number of previously received second-line anti-TB drugs (OR, 1.3; 95% CI, 1.1–1.5), and
female sex (OR, 3.2; 95% CI, 1.1–8.3) were significantly associated with XDR TB in crude analyses. After controlling
for other factors in a multivariable model, cumulative previous treatment duration remained significantly associated
with XDR TB (OR, 5.8; 95% CI, 1.0–61). Subjects with XDR TB were more likely to produce culture-positive
sputum at 6 months, compared with patients with non–multidrug resistant TB (risk ratio, 13; 95% CI, 5.1–53).
Kanamycin resistance was found to be predictive of 6-month culture positivity after adjustment for ofloxacin and
streptomycin resistance (risk ratio, 3.9; 95% CI, 1.9–11).
Conclusions. XDR TB was found to be associated with the cumulative duration of previous treatment with
second-line TB drugs among subjects in a tertiary care TB hospital. Patients with XDR TB were more likely to
not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial
susceptibility to both fluoroquinolones and kanamycin but not to streptomycin.
Extensively drug-resistant (XDR) tuberculosis (TB) has
recently emerged as a global health problem, threat-
ening the success of TB-control programs worldwide
[1–4]. A global survey of supranational reference lab-
oratories for TB isolates collected during 2000–2004
identified XDR TB in 17 countries and estimated that
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10% of the sampled multidrug-resistant (MDR) TB
strains were XDR [1]. All TB isolates received by the
South Korean National Reference Laboratory (Korean
Institute of Tuberculosis, Seoul) during this period were
included in this survey and among these MDR TB iso-
lates 15% were further classified as XDR TB.
South Korea has a relatively high burden of TB for
an industrialized country (73 cases per 100,000 persons
in 2005) [5]. However, this is a substantial decrease
from 1965, when the incidence was 668 cases per
100,000 persons, and the change reflects the success of
South Korea’s national TB program, which has focused
mainly on treating new cases of TB [6]. Health care
centers in South Korea do not use directly observed
therapy; nonetheless, health professionals make an ef-
fort to ensure compliance with treatment by contacting
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Table 1. Baseline characteristics of study subjects.
Characteristic
Patients with
newly diagnosed
tuberculosis
(n p 91)
Previously
treated patients
(n p 159)
Male sex 78 (86) 131 (82)
Age, median years (range) 45 (20–78) 44 (21–74)
Education (n p 247)
University or professional school 5 (6) 20 (13)
Middle, high, or night school 57 (63) 100 (64)
No formal education/elementary school 28 (31) 37 (24)
Occupation (n p 218)
Construction or factory worker 32 (41) 44 (31)
Unemployed 18 (23) 28 (20)
Service sector 12 (15) 35 (25)
Professional/office work 4 (5) 17 (12)
Agriculture/aquaculture 7 (9) 9 (6)
Other 5 (6) 7 (5)
Contact with person with tuberculosis in the past year (n p 217) 11 (14) 34 (24)
Purchased antibiotics in the previous 2 years (n p 216)
Once per month 8 (10) 34 (24)
More than once per month 9 (12) 31 (22)
No 60 (78) 74 (53)
Diabetes mellitus 16 (18) 30 (19)
Hepatitis B 3 (3) 12 (8)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
patients who default. With this system, cure rates for new cases
had reached 80% by 1994—higher than the 75% average for
national TB programs that employed the directly observed ther-
apy strategy in 2006 [7, 8]. With the introduction of stan-
dardized therapy in the 1980s, South Korea has seen a decrease
in the prevalence of drug-resistant TB (from 23.8% in 1980 to
5.8% in 1995) among persons with new cases and a decrease
in the rate of MDR TB (from 27.5% in 1994 to 7.1% in 1998)
among persons with previously treated cases [6, 9]. Although
the reported decreases in the incidence of TB and in the prev-
alence of drug-resistant TB are impressive, the battle against
TB in South Korea is hardly over. For instance, it is not known
whether similar success was seen in the private sector, which
treats a greater number of recurrent and drug-resistant cases
of TB, which have a higher default rate [9]. More recently, the
rate of MDR TB among newly diagnosed cases has increased
slightly, from 1.6% in 1994 to 2.4% in 2003 [10].
In 2005, a prospective cohort study of MDR TB was initiated
at the National Masan Tuberculosis Hospital (Masan, South
Korea). The objectives of this study were to characterize host
and bacterial strain characteristics related to the development
and progression of MDR TB and to collect baseline laboratory
data for clinical trials in this patient population.
METHODS
Study site and study population. Subjects included in this
analysis were those enrolled in a prospective observational
cohort study at a tertiary TB care center in South Korea. All
new patients with TB who were admitted to the hospital were
asked to participate in the study if they were at least 20 years
of age, had clinical signs and symptoms suggestive of TB, had
Ziehl-Neelsen acid-fast bacilli–positive sputum specimens,
and were not pregnant. Patients who were subsequently found
to be culture-negative for Mycobacterium tuberculosis or to be
HIV positive were withdrawn from the study. Subjects who
had received !30 days of previous TB treatment were assigned
to cohort A, and those who had received 30 days of treat-
ment were enrolled in cohort B [11]. After the subject pro-
vided informed consent, an interview was conducted to collect
demographic, epidemiologic, and clinical information. Pa-
tients’ medical records were abstracted to collect detailed in-
formation about comorbidities and treatment history. Pa-
tients were observed monthly until the completion of the
prescribed treatment regimen. Treatment outcome definitions
for cure, failure, and default followed the guidelines of the
World Health Organization [8].
Data collection and quality and protocol compliance, in-  at Y
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Table 2. Treatment histories among 123 previously treated subjects with detailed previous treatment histories.
Characteristic Value
Median no. of previous treatments (range) 3 (1–15)
Median no. of second-line tuberculosis drugs reported to have ever been prescribed (range) 3 (0–10)
History of at least 1 incomplete tuberculosis treatment regimen (n p 141) 117 (83)
Cumulative duration of previous treatments (n p 123)
8 months 29 (24)
18 months to 18 months 32 (26)
118 months to 34 months 30 (24)
134 months 32 (26)
Treatment with the following drugs at least once in the pasta
HRZE exclusively 49 (40)
HRZE; plus fluoroquinolones; plus streptomycin, kanamycin, or amikacin; plus a bacteriostatic agent 41 (33)
HRZE plus any other combinations of drugs 16 (13)
Patient was not prescribed any of HRZE agents 17 (14)
NOTE. Data are no. (%) of patients, unless otherwise indicated. HRZE, isoniazid, rifampicin, pyrazinamide, and ethambutol.
a Indicates that treatment with the indicated drugs in the patient history, does not necessarily indicate that these were concurrently
administered although in the case of the first-line agents HRZE, these would normally be concurrent.
cluding occurrence of adverse events, were monitored by an
independent clinical research organization. Subjects included
in this analysis were those enrolled starting in May 2005 for
whom drug susceptibility test results were available as of 1
December 2006 ( ). This study was reviewed and ap-np 250
proved by the institutional review boards of the National Masan
Tuberculosis Hospital and the National Institute of Allergy and
Infectious Diseases of the National Institutes of Health (Be-
thesda, MD).
Laboratory methods. Sputum specimens obtained from
each participant were processed using sodium hydroxide and
N-acetyl-l-cysteine, were screened for acid-fast bacilli with the
Ziehl-Neelsen staining method, and were cultured in duplicate
with a MB/BacT liquid culture system (bioMe´rieux) and Ogawa
agar slants (egg-based medium; Shinyang Chemical). Drug sus-
ceptibility testing (DST) was performed on Lo¨wenstein Jensen
agar slants containing the relevant anti-TB drugs. Growth of
11% for isoniazid, rifampicin, and p-aminoslicylic acid (PAS)
or of 10% in the control in Lo¨wenstein Jensen media for all
other drugs [12] indicated resistance. Isolates were tested for
resistance to critical concentrations of isoniazid (0.2 mg/mL),
rifampicin (40 mg/mL), ethambutol (2.0 mg/mL), streptomycin
(10 mg/mL), kanamycin (40 mg/mL), ofloxacin (2.0 mg/mL),
ethionamide (40 mg/mL), cycloserine (30 mg/mL), and PAS (1
mg/mL). Resistance to pyrazinamide was determined by the
pyrazinamidase assay [13]. MDR TB isolates were defined as
TB isolates resistant to at least isoniazid and rifampicin [8].
XDR TB was defined as MDR TB with additional resistance to
a fluoroquinolone and a second-line injectable anti-TB agent
(i.e., kanamycin, capreomycin, or amikacin) [4].
Data analysis. To assess the independent association of
selected predictor variables with XDR TB, we constructed a
multivariable logistic regression model that included variables
that were significantly associated with XDR TB at a P value
.20 in the crude analysis. Cumulative treatment duration was
calculated by summing the treatment duration for each TB
episode that had treatment start and end dates specified; the
resulting durations were categorized into quartiles. To deter-
mine significant risk factors for positive culture results at 6
months after enrollment, we constructed log-binomial regres-
sion models, using the likelihood ratio method to compute the
95% CIs for risk ratios. Statistical significance was set at P !
. When the number of subjects meeting specified model.05
conditions was !5, exact methods were used to derive the ORs,
their 95% CIs, and P values. For variables with missing infor-
mation, data analysis was conducted for patients with complete
information. All statistical analyses were performed using SAS
software for Windows, version 9.1 (SAS Institute).
RESULTS
Description of the study population. Of the 250 people in-
cluded in our analysis, 159 (64%) had been previously treated
for TB (cohort B). The median age of these subjects was 44
years, and 209 (84%) were male (table 1). This patient pop-
ulation had significant prior treatment history: the median
number of previous treatment episodes was 3 (range, 1–15),
with a mean cumulative duration of 28 months (range, 1–
189 months). The median number of second-line anti-TB
drugs previously prescribed was 3 (range, 0–10). Overall, 117
(83%) of the previously treated patients had not completed
at least 1 prior treatment (table 2). Detailed records of prior
treatment regimens were available for 123 patients (77%) in
cohort B. Forty-nine (40%) of these patients had been pre-
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Figure 1. Drug resistance of isolates from patients in cohort A (i.e., patients with newly diagnosed tuberculosis) and cohort B (previously treated
patients). The figure shows the percentage of isolates resistant to the individual agent (or combination of agents). CS, cylcoserine; EMB, ethambutol;
ETH, ethionamide; INH, isoniazid; KM, kanamycin; MDR, multidrug resistance; OFX, ofloxacin; PAS, p-aminoslicylic acid; PZA, pyrazinamide; RIF, rifampicin;
SM, streptomycin; XDR, extensive drug resistance.
viously treated only with isoniazid, rifampicin, pyrazinamide,
and/or ethambutol. An additional 41 patients (33%) had also
received treatment with a fluoroquinolone, an aminoglyco-
side, and a second-line bacteriostatic drug (not necessarily
simultaneously) (table 2).
On the basis of DST data, 113 subjects (45%) were classified
as having MDR TB, and 26 (10%) were further classified as
having XDR TB. Among previously treated subjects, 65% had
MDR TB, and 16% had XDR TB. Among patients who had
received a new diagnosis, 10% had MDR TB, and none had
XDR TB (figure 1).
Risk factors for XDR TB. We examined sex, age, a diagnosis
of diabetes, formal education level, the total number of second-
line agents in the treatment history, the cumulative total du-
ration of treatment, and a history of treatment interruption for
association with XDR TB disease. Female sex, the number of
second-line drugs taken in the past, and cumulative duration
of treatment of 18–34 months were significantly associated with
XDR TB in the univariate analysis. In a multivariate analysis,
cumulative treatment duration of 18–34 months remained sig-
nificant, and such subjects were 5.8 times (95% CI, 1.0–61
times) more likely to have XDR TB, compared with persons
who were treated for 8 months (table 3). In addition, there
was an increasing prevalence of drug resistance associated with
longer treatment history ( , by test for trend).Pp .012
To investigate more thoroughly the association between pre-
vious treatment and drug resistance, we compared patients with
new diagnoses, those who had received standard first-line ther-
apy only, and those who had received first-line therapy, a flu-
oroquinolone, an aminoglycoside, and a bacteriostatic drug
(figure 2A). In this analysis, a marked increase in the prevalence
of MDR and XDR TB was apparent with increased prior ex-
posure to antitubercular agents.
The high prevalence of fluoroquinolone resistance in South
Korean patients with TB. In both cohorts, we detected re-
sistance to drugs that had not been prescribed for the treatment
of their TB. This was most striking with respect to ofloxacin
resistance. Although the prevalence of ofloxacin resistance was
higher for patients who had been treated with a fluoroquino-
lone in the past (83%) than among subjects who had no record
of having received a fluoroquinolone (54%), a high proportion
of ofloxacin resistance could not be explained by reported flu-
oroquinolone use (figure 2B). The odds of ofloxacin resistance
were increased 5.1-fold among persons who reported purchases
of antibiotics unrelated to their TB treatment once per month,
relative to those who reported none (table 4). There was an
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Table 3. Association of demographic and clinical factors with extensively drug-resistant (XDR) tuberculosis (TB).
Variable
No. of
patients with
XDR TB/total
no. of patients
(n p 250) OR (95% CI) Adjusted OR (95% CI)a P b
Sex
Male 17/209 1.0 1.0
Female 9/41 3.2 (1.1–8.3) 2.3 (0.67–7.3)
Age
144 years 13/123 1.0 …
44 years 13/127 1.0 (0.40–2.4) …
Diabetes
No 18/204 1.0 1.0
Yes 8/46 2.2 (0.76–5.7) 2.1 (0.64–6.9)
Education
High school or less 21/222 1.0 …
University or professional school 5/25 2.4 (0.63–7.5) …
Previously treated patients
No. of agents previously prescribed … 1.3 (1.1–1.5) …
Cumulative duration of past treatment
8 months 2/29 1.0 1.0
18 months to 18 months 4/32 1.9 (0.25–23) 2.1 (0.26–26)
118 months to 34 months 9/30 5.6 (1.0–59) 5.8 (1.0–61)
134 months 10/32 6.0 (1.1–62) 5.4 (0.96–58) .012c
History of at least 1 incomplete TB treatment regimen
No 2/24 1.0 …
Yes 23/117 2.7 (0.59–25) …
a Adjusted for sex, diabetes, and cumulative duration of treatment; not adjusted for second-line anti-TB treatment because of collinearity with cumulative
duration.
b Determined by test for trend.
c Cumulative treatment duration categories were treated as an ordinal variable.
apparent increase in odds of ofloxacin resistance associated with
more frequent purchases of antibiotics, but the overall trend
was only marginally significant ( ).Pp .07
Clinical consequences of XDR TB. Patients who are re-
ferred to National Masan TB Hospital are usually referred while
already receiving a drug regimen prescribed by their primary
physician. Typically, this regimen is not changed for the first 6
months after admission to the hospital. After 6 months, both
DST results and clinical response are reviewed before a rec-
ommendation is made regarding whether to continue or change
the regimen for those patients whose sputum culture results
remain positive. As of 1 December 2006, results for 6-month
cultures were available for 104 patients. Three (6%) of the 49
patients whose isolates were not MDR at baseline had positive
culture results at 6 months, whereas 8 (21%) of the 39 patients
with MDR TB and 13 (81%) of the 16 patients with XDR TB
had positive culture results at 6 months. Patients with XDR TB
were 13 times (95% CI, 5.1–53 times) more likely to produce
culture-positive sputum specimens at 6 months than were those
who did not have MDR TB at baseline.
We used the 6-month sputum culture positivity data to com-
pare outcomes among 55 patients with MDR TB who were
receiving various second-line regimens to which their isolate
was either resistant or susceptible (table 5). Patients with kan-
amycin-resistant TB at baseline were 3.9 times (95% CI, 1.9–
11 times) more likely to have positive sputum culture results
than were those with kanamycin-susceptible TB (95% CI, 1.6–
27 times). On the other hand, patients with ofloxacin- and
streptomycin-resistant TB were only marginally more likely to
have positive sputum culture results at 6 months (OR for of-
loxacin, 1.9 [95% CI, 0.43–12]; OR for streptomycin, 1.4 [95%
CI, 0.25–7.2]) than were patients with strains susceptible to
those agents (table 5).
DISCUSSION
All of the XDR TB cases identified in this study were among
non-HIV infected patients previously treated for TB, with no
evidence of geographic clustering. The strongest predictors of
having XDR TB were cumulative duration of prior treatment
episodes and the number of second-line TB drugs previously
prescribed. The subjects with XDR TB in a recent South African
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Figure 2. Drug resistance patterns according to treatment history. A, Drug resistance profile by treatment history (pan-susceptible, susceptible to
all drugs tested; non-MDR DR, any drug resistance but not multidrug resistance; MDR, non-XDR, multidrug resistant but susceptible to either a
fluoroquinolone [FLQ] of an injectable, according to the definition). B, Percentage of ofloxacin-resistant isolates recovered from patients with a history
of receiving ofloxacin, a history of receiving any FLQ, or no history of previous treatment with a fluoroquinolone. AK, amikacin; HRZE, isoniazid,
rifampicin, pyrazinamide, and ethambutol; KM, kanamycin; SM, streptomycin.
Table 4. Association of self-reported antibiotic purchase 2
years before study enrollment and ofloxacin resistance at base-
line among patients with newly diagnosed tuberculosis.
Antibiotic purchase
in past 2 years
No. of
fluoroquinolone
recipients/total
no. of patients OR (95% CI) P a
None 22/60 1.0
!1 per month 4/9 1.4 (0.25–55)
1 per month 6/8 5.1 (0.81–55) .07
NOTE. Analysis is based on data for 77 patients with complete antibiotic
purchase information.
a Determined by test for trend.
study consisted entirely of HIV-infected patients with low CD4
cell counts [3]. In that study, 55% of patients had not been
previously treated, and nosocomial transmission was strongly
suspected. In our study, the strong correlation with total du-
ration of previous treatment suggests that XDR TB in South
Korea may have involved more acquisition of resistance
through lengthy and inappropriate treatment, although trans-
mission is possible, as was observed in South Africa. More-
detailed resistance history and molecular analysis of XDR TB
cases in South Korea will be necessary to determine whether
this phenomenon is affected by the nature of the patient pop-
ulation described here.
Women were significantly more likely than men to have XDR
TB. TB diagnosis and DST may be delayed among female pa-
tients in South Korea, making treatment more difficult and
inappropriate chemotherapeutic regimens more likely. Diag-
nostic delays among female patients have also been reported
in other East Asian countries, such as Taiwan and Vietnam [14,
15]. It is also possible that the social standard for referring
patients to the hospital may be different for male and female
subjects; thus, providers may feel reluctant to refer female pa-
tients with less complicated infection to a tertiary care center.
In our study, ofloxacin-resistant TB was highly prevalent
among patients who had no record of having been treated with
a fluoroquinolone for TB and was associated with frequent
purchases of antibiotics. Patients with newly diagnosed TB may
have been exposed to a fluoroquinolone if the diagnosis of TB
was delayed but treatment was given either via prescription or
over-the-counter drugs. Although Korea put into effect a policy
to ban nonprescription antibiotics in 2000 [16], over-the-
counter antibiotics were still available during the ensuing years.
Fluoroquinolone resistance and empirical use of fluoroquino-
lones have been associated with poor treatment outcome [17,
18] and delayed diagnosis [19] among patients with TB. Sim-
ilarly high rates of fluoroquinolone resistance have been re-
ported from other Asian countries [20], raising concerns about
the utility of fluoroquinolones currently in clinical trials for TB
treatment (i.e., moxifloxacin and gatifloxacin). These findings
contrast with the situation in Latvia, the site of a retrospective
cohort analysis of 204 patients with MDR TB, where fluoro-
quinolone resistance was found to be very low [21].
As expected with the lack of effective drugs, subjects from
whom XDR TB isolates were recovered at baseline were more
likely to have positive culture results at 6 months than were
those with MDR TB or non-MDR TB. We also found that
kanamycin resistance was more predictive of positive 6-month
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Table 5. The risk of positive 6-month culture results among patients with multidrug-resistant
tuberculosis, by baseline drug susceptibility.
Variable
No. of patients with
positive culture results/
total no. of patients
(n p 55) RR (95% CI) Adjusted RR (95% CI)a
Kanamycin susceptibility
Susceptible 6/37 1.0 1.0
Resistant 15/18 5.1 (2.6–13) 3.9 (1.9–11)
Ofloxacin susceptibility
Susceptible 2/18 1.0 1.0
Resistant 19/37 4.6 (1.6–27) 1.9 (0.43–12)
Streptomycin susceptibility
Susceptible 6/21 1.0 1.0
Resistant 15/34 1.5 (0.76–3.8) 1.4 (0.88–2.9)
NOTE. RR, risk ratio.
a Adjusted for the listed groups.
culture results than was ofloxacin or streptomycin resistance
among patients with MDR TB. Kanamycin and streptomycin
are both aminoglycosides and share a common mechanism of
action, which is consistent with the nearly identical in vitro
growth inhibitory and bactericidal effects of these 2 agents,
which show identical killing kinetics of intracellular TB in hu-
man macrophages [22]. These 2 agents also have similar dos-
ages, administrative schedules, routes of administration, max-
imum serum concentrations, and half-lives [23]. However,
streptomycin and kanamycin differ markedly in 2 pharmaco-
kinetic parameters: the degree of protein binding (streptomycin
is 35%–57% protein bound, whereas kanamycin is effectively
unbound) and the volume of distribution (76.4–115.4 L for
streptomycin, compared with 13.2–28 L for kanamycin) [23,
24]. One possible reason is that streptomycin, being both pro-
tein bound and well distributed in tissue, simply has a lower
effective concentration at the pulmonary surface where sputum
is being sampled.
Our study had several limitations. First, the prevalence es-
timates of MDR TB and XDR TB cannot be extrapolated to
the general population, because the study population came
from a referral hospital that specializes in treating patients with
severe TB. Also, drug susceptibility tests of injectible drugs,
such as capreomycin and amikacin, and fluoroquinolones other
than ofloxacin were not performed. Thus, it is likely that the
prevalence of XDR TB was underestimated. Moreover, the
cross-sectional nature of our study did not allow us to deter-
mine the drug resistance status of patients prior to the regimen
that they had previously taken; thus, it is possible that drug
resistance may have predated the lengthy regimen. Information
on variables such as cumulative duration of treatment and pre-
vious treatment regimen were missing for a portion of patients.
It is uncertain how this misclassification would affect the as-
sociations, but the bias would have to be substantial for the
direction of the associations to change.
In summary, we have documented a significant burden of
XDR TB associated with prior treatment with second-line drugs
among previously treated patients, as well as a high proportion
of fluoroquinolone resistance among patients with newly di-
agnosed cases. Fluoroquinolone resistance, at least in this pop-
ulation, has already significantly penetrated circulating MDR
TB strains, limiting the utility of this class of compounds. The
development of fluoroquinolone resistance in these TB strains
may have been the consequence of widespread availability of
these agents without prescription control for the treatment of
non-TB disease. This prospective evaluation of treatment reg-
imens used for MDR TB and XDR TB has also led us to the
surprising finding that kanamycin susceptibility may be a more
important predictor of outcome for patients with MDR TB
than is fluoroquinolone susceptibility. These results underscore
the urgent need for improved strategies for prevention, detec-
tion, and cure of MDR TB and XDR TB through development
of new therapeutic agents, faster diagnostics, and greater aware-
ness of drug-resistant TB in the medical community. In the
context of South Korea, improving the follow-up of patients
with TB in both the public and private sector will contribute
to reduction in drug resistance and TB overall.
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